GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
Nvidia Eyes $2.5 Billion Investment in Thinking Machines Lab 
France Targets Shein, Temu With Fast-Fashion Fees 
Anthropic Nears $15 Billion Credit Deal Ahead of IPO 
OpenAI Nears Astra AI Model Launch With Safety Focus 
Milei Threatens Falkland Oil Firms With Sanctions 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
South Korea, US Discuss Chip Investments Amid Tariff Plans 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
Lynas Rare Earths Shares Rise After Takeover Talks Revealed 
Xiaomi Shares Jump on Europe EV Expansion Plan 
Add as a preferred source on Google
EDEN PRAIRIE, Minn., March 07, 2018 -- CHF Solutions (Nasdaq:CHFS), today announces that it will be exhibiting at the 67th Annual Scientific Sessions of the American College of Cardiology (ACC) from March 10-12 in Orlando, Florida.
The company will be exhibiting its Aquadex FlexFlow System and can be found on the exhibition floor at the Orange County Convention Center, Booth #1505 during the conference.
“Attending the ACC Conference is an important venue to demonstrate the clinical and economic value of our Aquadex FlexFlow System. We look forward to connecting with the Cardiology community at the ACC Conference and further educating the attendees on the value of our Ultrafiltration System,” said Jim Breidenstein, chief commercial officer of CHF Solutions.
About CHF Solutions
CHF Solutions, Inc. (Nasdaq:CHFS) is a medical device company focused on commercializing the Aquadex FlexFlow system for Aquapheresis® therapy. The Aquadex FlexFlow system is indicated for temporary (up to eight hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended (longer than 8 hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. All treatments must be administered by a healthcare provider, under physician prescription, both of whom having received training in extracorporeal therapies. The company's mission is to predict, measure, and control patient fluid balance through science, collaboration, and innovative medical technology. CHF Solutions is a Delaware corporation headquartered in Minneapolis, Minnesota with wholly owned subsidiaries in Australia and Ireland. The company has been listed on the NASDAQ Capital Market since February 2012.
CONTACTS:
INVESTORS:
Claudia Napal Drayton
Chief Financial Officer
CHF Solutions, Inc.
952-345-4205
[email protected]
-or-
Bret Shapiro
Managing Partner
CORE IR
516-222-2560
[email protected]
www.coreir.com
MEDIA
Jules Abraham
JQA Partners, Inc.
917-885-7378
[email protected]
